Fig. 7: CD83 is expression is skewed in the CCR7+PD1+ T-cell population within the tumor tissue.

a, b CD83 expression was analyzed in TIL samples from patients with gynecologic malignancies. The data shown are representative flow cytometry plots (a) and the mean fluorescence intensity of CD83 in the CD8⁺ T-cell populations (b), (n = 10 different samples, repeated measures one-way ANOVA with multiple comparison test). c Single-cell RNA-sequencing data of TIL from various cancer types were analyzed for the proportion of CD83⁺ cells within the CCR7⁺PD1⁺, CCR7^-PD1⁺, and PD1⁻ CD8⁺ T cell populations (n = 12 datasets, repeated measures one-way ANOVA with multiple comparison test). d In the GSE120575 data, the proportion of CD83⁺CCR7⁺ cells within the total CD8⁺ T cells were compared among the samples collected before or after treatment with immune checkpoint inhibitors in the responder or non-responder patients (n = 1005, 1587, 1082, and 3067 cells, *P < 0.05, **P < 0.01, Fisher’s exact test with multiple testing correction). e The frequency of CD83⁺CCR7⁺ cells was calculated in the individual patients’ samples with or without response to immune checkpoint inhibitors using the GSE120575 dataset (n = 9 or 10 patients, unpaired two-tailed t-test; NS not significant).